FDA pulls On­copep­tides' Pepax­to in­di­ca­tion, open­ing the door for dan­gling ac­cel­er­at­ed ap­proval en­force­ment

In a move all but en­sured af­ter an over­whelm­ing­ly neg­a­tive ad­comm vote this Sep­tem­ber, the FDA is yank­ing On­copep­tides’ dan­gling ac­cel­er­at­ed ap­proval. And there may …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER